Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Botulinum Toxin-A in Children With Dysfunctional Voiding or Refractory Nocturnal Enuresis
NCT07523477Recruiting
- Sponsor
- Tanta University
- Start
- Jun 2025
- Primary completion
- Dec 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label, single-arm trial of botulinum toxin type A in Dysfunctional voiding (DV) and refractory nocturnal enuresis (RNE), sponsored by Tanta University. Primary endpoint: Success rate at 24 hours. Started Jun 2025; status: recruiting.
02
Drugs
botulinum toxin type A
03
Conditions
Dysfunctional voiding (DV)refractory nocturnal enuresis (RNE)
Beyond the preview
Go deeper on NCT07523477.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07523477.